Slc30A10 Zinc Transporter 10 plays an important role in the study of neurodegenerative diseases. This page provides comprehensive information about this topic, including its mechanisms, significance in disease processes, and therapeutic implications.
Solute carrier family 30 member 10 (SLC30A10), also known as Zinc Transporter 10 (ZnT10), is a critical membrane protein encoded by the SLC30A10 gene on chromosome 1q31.3. This protein belongs to the SLC30 family of zinc transporters, which are essential for cellular metal homeostasis. While initially characterized as a zinc transporter, SLC30A10 has emerged as a crucial regulator of manganese metabolism, and mutations in this gene are directly linked to a rare but devastating neurodegenerative disorder characterized by manganese accumulation in the brain. This page provides a comprehensive overview of SLC30A10, including its molecular function, expression patterns, disease associations, and therapeutic implications.
The SLC30A10 gene (NCBI Gene ID: 55532; Ensembl ID: ENSG00000196660) is located on the long arm of chromosome 1 at position q31.3. The gene spans approximately 7.5 kilobases and consists of multiple exons that encode a protein of 460 amino acids with a molecular weight of approximately 50 kDa. The UniProt identifier for SLC30A10 is Q6XR72, and the protein is classified under the cation diffusion facilitator (CDF) family, also known as the zinc-iron permease (ZIP) family in some nomenclature systems.
The SLC30A10 protein contains six transmembrane domains, a characteristic feature of CDF family transporters. The protein topology includes an intracellular N-terminus and C-terminus, with the transmembrane domains forming a channel that facilitates the movement of metal ions across cellular membranes. Like other members of the SLC30 family, SLC30A10 possesses the characteristic histidine-rich loop between transmembrane domains IV and V, which is believed to be involved in metal binding and selectivity.
SLC30A10 functions as a divalent metal transporter, with primary specificity for zinc and manganese. The protein localizes to the plasma membrane and intracellular compartments, including the endoplasmic reticulum and Golgi apparatus, where it mediates the efflux of metal ions from the cytoplasm to extracellular spaces or into intracellular organelles. This efflux function is crucial for maintaining intracellular metal homeostasis and protecting cells from metal-induced toxicity.
The transport mechanism of SLC30A10 involves the coupling of metal efflux to the exchange of protons or other cations, a process driven by the electrochemical gradient across the membrane. In vitro studies have demonstrated that SLC30A10 can transport zinc, manganese, cadmium, and cobalt, with varying affinities. However, its physiological significance appears to be most critical for manganese homeostasis, as evidenced by the severe neurological phenotype observed in individuals with loss-of-function mutations.
Manganese is an essential trace element required for the function of numerous enzymes, including arginase, glutamine synthetase, and manganese superoxide dismutase. However, excess manganese is highly neurotoxic, leading to oxidative stress, mitochondrial dysfunction, and neuronal death. SLC30A10 plays a pivotal role in protecting neurons from manganese toxicity by facilitating the efflux of this metal from cells.
In the brain, SLC30A10 is particularly important in regions with high metabolic activity and susceptibility to metal-induced neurodegeneration, including the basal ganglia, substantia nigra, and cerebellum. The protein helps maintain optimal manganese levels in these regions by promoting its removal from neurons and astrocytes, thereby preventing the accumulation that leads to toxicity.
While manganese transport is the most clinically relevant function of SLC30A10, the protein also contributes to zinc homeostasis. Zinc is the second most abundant trace metal in the human body and serves as a structural and catalytic cofactor for numerous proteins. SLC30A10-mediated zinc efflux helps regulate intracellular zinc concentrations, which is important for neuronal signaling, synaptic plasticity, and overall brain function.
Dysregulation of zinc homeostasis has been implicated in various neurological disorders, including Alzheimer's disease, epilepsy, and ischemic stroke. The role of SLC30A10 in zinc transport suggests that it may contribute to the pathogenesis of these conditions, although this remains an area of active investigation.
SLC30A10 has been shown to localize to mitochondria in some cell types, where it may contribute to mitochondrial metal handling and function. Manganese accumulation in mitochondria leads to impaired oxidative phosphorylation, increased reactive oxygen species (ROS) production, and ultimately cell death. By facilitating manganese efflux, SLC30A10 helps maintain mitochondrial integrity and protects neurons from metal-induced mitochondrial dysfunction.
The protein also appears to have indirect neuroprotective effects through its role in preventing metal-induced oxidative stress. Both zinc and manganese can catalyze the production of ROS through Fenton-like reactions when present in excess. By regulating the intracellular concentrations of these metals, SLC30A10 helps prevent oxidative damage to lipids, proteins, and DNA.
SLC30A10 exhibits a broad expression pattern across multiple tissues, with particularly high levels in the brain, liver, and kidney. In the brain, expression is most prominent in the basal ganglia, substantia nigra, and cerebellum – regions that are particularly vulnerable to manganese toxicity and are involved in movement control. This expression pattern explains the predominant neurological manifestations observed in individuals with SLC30A10 deficiency.
In the peripheral organs, SLC30A10 is highly expressed in the liver and kidneys, which are the primary organs responsible for manganese excretion. The hepatic and renal expression of SLC30A10 suggests a role in systemic manganese homeostasis and detoxification, in addition to its local protective function in the brain.
Expression studies have also detected SLC30A10 in the pancreas, small intestine, and placenta, indicating broader roles in systemic metal metabolism. The multi-tissue expression pattern underscores the importance of SLC30A10 in maintaining metal homeostasis throughout the body.
The first and most well-characterized disease associated with SLC30A10 mutations is Hypermanganesemia with Dystonia, Polycythemia, and Cirrhosis (HMDPC), also known as SLC30A10-related锰代谢障碍 (SLC30A10-related manganese metabolism disorder). This autosomal recessive disorder was first described in 2012 and is characterized by the triad of manganese accumulation in the blood and brain, early-onset dystonia, polycythemia, and hepatic cirrhosis.
Patients with HMDPC typically present in childhood with progressive dystonia, which often begins in the lower limbs and progresses to involve the upper limbs and trunk. The dystonia can become severely disabling, leading to gait disturbances, postural instability, and eventually complete immobility. In addition to dystonia, patients may develop parkinsonism, including bradykinesia, rigidity, and resting tremor, which can be indistinguishable from idiopathic Parkinson's disease.
The polycythemia observed in HMDPC results from increased erythropoietin production in response to tissue hypoxia caused by manganese deposition in the brain. This secondary erythrocytosis is a characteristic feature that helps distinguish SLC30A10-related disease from other forms of manganese metabolism disorders.
Hepatic involvement is another hallmark of HMDPC, with patients developing cirrhosis that can progress to hepatic failure. The liver pathology is thought to result from both direct manganese toxicity and secondary oxidative stress. In some cases, liver transplantation has been considered, although the neurological symptoms may not improve following liver replacement due to continued manganese accumulation in the brain.
SLC30A10 mutations have also been implicated in a broader phenotype of parkinsonism-dystonia syndrome, which encompasses the movement disorders observed in HMDPC. The term "parkinsonism-dystonia syndrome" reflects the overlapping features of parkinsonism (bradykinesia, rigidity, tremor) and dystonia (sustained muscle contractions causing abnormal postures) seen in affected individuals.
Genetic studies have identified multiple pathogenic variants in the SLC30A10 gene, including nonsense mutations, frameshift mutations, and missense mutations that result in loss of transporter function. The most common mutation is a homozygous deletion that results in a complete loss of protein function, although compound heterozygous mutations have also been reported.
SLC30A10-related disorders must be differentiated from other conditions causing manganese accumulation, including:
The pathophysiology of SLC30A10-related disease involves the disruption of cellular manganese efflux, leading to progressive manganese accumulation in the brain and other organs. Manganese is primarily eliminated from the body through the liver via biliary excretion. The liver expresses high levels of SLC30A10, which is thought to facilitate the transport of manganese into bile for excretion. Loss of SLC30A10 function impairs this excretory pathway, resulting in increased blood manganese levels and subsequent deposition in the brain.
In the brain, manganese accumulates primarily in the basal ganglia, particularly the globus pallidus, which has the highest iron content and is therefore susceptible to metal deposition. The precise mechanisms by which manganese causes neuronal injury are multifactorial and include:
Mitochondrial dysfunction: Manganese accumulates in mitochondria and interferes with oxidative phosphorylation, leading to impaired energy production and increased ROS generation.
Oxidative stress: Manganese catalyzes the production of ROS through Fenton-like reactions, causing damage to lipids, proteins, and DNA.
Protein aggregation: Manganese has been shown to promote the aggregation of α-synuclein and other proteins implicated in neurodegenerative diseases.
Neuroinflammation: Manganese activates microglia and promotes the release of pro-inflammatory cytokines, contributing to neuroinflammation.
Dopaminergic neuron vulnerability: The substantia nigra pars compacta, which contains the dopaminergic neurons that are lost in Parkinson's disease, is particularly vulnerable to manganese toxicity.
Several animal models have been developed to study SLC30A10 function and the pathophysiology of manganese-induced neurodegeneration. Knockout mice lacking Slc30a10 exhibit increased tissue manganese levels, liver dysfunction, and neurological abnormalities, although the phenotype is less severe than in humans, possibly due to compensatory mechanisms in mice.
Zebrafish models have also been used to study SLC30A10, with knockdown of the zebrafish ortholog leading to manganese accumulation and developmental abnormalities. These models have provided valuable insights into the role of SLC30A10 in development and metal homeostasis.
The clinical presentation of SLC30A10-related disease typically begins in early childhood, with most patients presenting before age 10. The initial symptoms often include gait difficulty due to lower limb dystonia, which progresses over several years to involve the trunk and upper limbs. In some cases, the disease may present with more prominent parkinsonian features, including bradykinesia and rigidity.
Diagnosis relies on the combination of clinical features, elevated blood manganese levels, and genetic testing. Magnetic resonance imaging (MRI) of the brain typically shows T1-weighted hyperintensity in the basal ganglia, particularly the globus pallidus, which is characteristic of manganese deposition. Genetic testing for SLC30A10 mutations confirms the diagnosis and allows for accurate genetic counseling.
Currently, there is no cure for SLC30A10-related disease, and treatment is primarily supportive and symptomatic. Several therapeutic strategies have been explored:
Chelation therapy: Agents such as ethylenediaminetetraacetic acid (EDTA) have been used to accelerate manganese excretion, with variable results. Some patients show improvement in neurological symptoms following chelation, while others show little benefit.
Antioxidant therapy: Given the role of oxidative stress in manganese-induced neurodegeneration, antioxidants such as vitamin E and coenzyme Q10 have been explored as potential neuroprotective agents.
Dystonia management: Botulinum toxin injections, deep brain stimulation (DBS), and physical therapy can help manage dystonia symptoms in some patients.
Liver transplantation: In patients with severe hepatic involvement, liver transplantation may be considered, although it does not typically reverse the neurological symptoms due to already established brain manganese deposition.
Ongoing research is focused on developing better understanding of SLC30A10 function and identifying novel therapeutic approaches. Gene therapy approaches aimed at restoring SLC30A10 expression are currently being investigated in preclinical models. Additionally, high-throughput screening of small molecules that can enhance transporter function or reduce manganese toxicity may lead to new treatment options.
SLC30A10 belongs to the SLC30 family of zinc transporters, which includes ten members (SLC30A1-10) in humans. Other closely related transporters include SLC30A1 (ZnT1), SLC30A3 (ZnT3), and SLC30A5 (ZnT5), which are also involved in zinc homeostasis. For manganese transport, SLC39A14 (ZIP14) represents the major importer and is functionally opposite to SLC30A10.
Slc30A10 Zinc Transporter 10 plays an important role in the study of neurodegenerative diseases. This page provides comprehensive information about this topic, including its mechanisms, significance in disease processes, and therapeutic implications.
The study of Slc30A10 Zinc Transporter 10 has evolved significantly over the past decades. Research in this area has revealed important insights into the underlying mechanisms of neurodegeneration and continues to drive therapeutic development.
Historical context and key discoveries in this field have shaped our current understanding and will continue to guide future research directions.
National Center for Biotechnology Information. "SLC30A10 solute carrier family 30 member 10 [Homo sapiens]." NCBI Gene. https://www.ncbi.nlm.nih.gov/gene/55532
Tuschl K, et al. "Mutations in SLC30A10 cause parkinsonism and dystonia with hypermanganesemia, polycythemia, and chronic liver disease." American Journal of Human Genetics. 2012;90(3):467-477.
Quadri M, et al. "SLC30A10 mutations in a family with parkinsonism and manganese metabolism disorder." Parkinsonism & Related Disorders. 2015;21(8):1015-1019.
Chen P, et al. "Manganese homeostasis in the nervous system." Journal of Neurochemistry. 2015;134(4):601-610.
Leyva-Illades D, et al. "SLC30A10 (ZnT10) regulates cellular manganese homeostasis and is targeted to the plasma membrane." Journal of Biological Chemistry. 2014;289(23):16740-16756.
Mukhopadhyay S, et al. "Manganese-induced neurotoxicity: new insights into the role of metal transporters." Neurotoxicology. 2020;78:130-139.
Xin Y, et al. "Zinc transporter ZnT10 (SLC30A10) deficiency induces dopaminergic neuron loss in a mouse model." Journal of Neurochemistry. 2021;157(5):1612-1625.
Hering D, et al. "Clinical spectrum, treatment, and follow-up of patients with SLC30A10-related manganese metabolism disorder." Movement Disorders. 2022;37(3):534-542.
Kim J, et al. "Zinc and manganese transporters: from structure to function in health and disease." Physiological Reviews. 2023;103(2):1021-1078.
Guo Y, et al. "Manganese and neurodegeneration: molecular mechanisms and therapeutic strategies." Ageing Research Reviews. 2024;87:101891.
Zoghbi HY, et al. "The emerging role of metal transporters in neurodegenerative diseases." Nature Reviews Neuroscience. 2023;24(8):477-492.